• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Provista Life Sciences Relocates GW Medical Technologies, RCP Diagnostics, Biomarker Technologies to New Headquarters

Posted on: Thursday, 18 January 2007, 18:00 CST

Provista Life Sciences LLC announced today it has relocated its headquarters to offices at 2400 Biltmore Circle, Ste. 1200, Phoenix, Arizona 85016. The relocation to a larger office space allows expansion of the three biotech diagnostic development companies overseen by Provista Life Sciences: GW Medical Technologies LLC, Biomarker Technologies LLC and RCP Diagnostics LLC. Provista will continue to lease office space at that address in Suite 1170, which will be converted to an on-site clinical diagnostics laboratory.

According to CEO William Gartner, "Relocating into larger headquarters allows Provista to more efficiently manage each operating unit's business resources. At the same time, we now have the ability to establish the clinical laboratory that will be pivotal to accelerating the commercialization of diagnostics technologies currently in the final testing stage."

Provista Life Sciences is an umbrella organization that identifies and acquires the rights to promising medical diagnostics technologies and then unifies their respective operational and business development activities under a singular management company.

About GW Medical Technologies LLC

GW Medical Technologies is focused on commercializing a blood test to diagnose Alzheimer's disease (AD). The LymPro Test® aims to provide a diagnosis of AD in a matter of days at a tenth the cost of current methods. There is no single definitive test for this disease at this time. The initial clinical study for the LymPro Test® demonstrated high sensitivity and specificity with clinical diagnosis and the potential to diagnose AD before the appearance of clinical symptoms. A second clinical trial will begin in the first quarter of 2007 after which, the firm intends to begin market introduction as a laboratory-developed test through its CLIA lab. For more information, visit the company's web site at www.gwmedtech.com.

About Biomarker Technologies LLC

Biomarker Technologies is focused on the commercialization of an early detection blood diagnostic for breast cancer. The BT Test™ aims to improve accuracy and convenience for patients. Currently, mammography is widely accepted for breast cancer screening but the technology has shortfalls. The BT Test™, used in conjunction with or separate from other imaging techniques, could eventually address more difficult to diagnose cases and expand patient outreach to encompass both those women for whom mammograms are not suitable and younger women who presently do not fall under current recommended guidelines for mammography. A second clinical trial is underway after which, the firm intends to introduce it as a laboratory-developed test. For more information, visit the company's web site at www.biomarkertech.com.

About RCP Diagnostics LLC

RCP Diagnostics is developing a screening diagnostic for women's estrogen-related cancers: ovarian, uterine, cervical and breast. The RCP-Dx Test™ is in development and initial clinical trials have demonstrated its potential as a cost-effective blood test to detect and improve the accuracy of existing diagnosis of these devastating diseases. A second clinical trial is underway after which, the firm intends to introduce it as a laboratory-developed test. For more information, visit the company's web site at www.rcpdiagnostics.com.

Provista Life Sciences' Background

Provista Life Sciences was established in 2006 as a biotechnology mezzanine development organization that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostics technologies into the domestic and global marketplace. For more information, visit the company's web site at www.provistals.com or call 602-224-5500.

Source: Business Wire

More News in this Category